MRSN vs. CLLS, CRDF, FBRX, HURA, CHRS, BHST, IKT, ACOG, ZURA, and CABA
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Alpha Cognition (ACOG), Zura Bio (ZURA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.
Cellectis has a net margin of -100.69% compared to Mersana Therapeutics' net margin of -212.94%. Cellectis' return on equity of -68.05% beat Mersana Therapeutics' return on equity.
Mersana Therapeutics presently has a consensus target price of $56.60, suggesting a potential upside of 692.72%. Cellectis has a consensus target price of $4.00, suggesting a potential upside of 38.41%. Given Mersana Therapeutics' higher probable upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than Cellectis.
93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Mersana Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.
In the previous week, Cellectis had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 3 mentions for Cellectis and 2 mentions for Mersana Therapeutics. Cellectis' average media sentiment score of 1.61 beat Mersana Therapeutics' score of 0.97 indicating that Cellectis is being referred to more favorably in the news media.
Cellectis has higher revenue and earnings than Mersana Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectis beats Mersana Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 9/12/2025 by MarketBeat.com Staff
Free MRSN Stock Alerts